journal
MENU ▼
Read by QxMD icon Read
search

Breast Care

journal
https://www.readbyqxmd.com/read/28228712/nordic-walking-and-the-isa-method-for-breast-cancer-survivors-effects-on-upper-limb-circumferences-and-total-body-extracellular-water-a-pilot-study
#1
Andrea Di Blasio, Teresa Morano, Giorgio Napolitano, Ines Bucci, Serena Di Santo, Sabina Gallina, Lucia Cugusi, Francesco Di Donato, Alberto D'Arielli, Ettore Cianchetti
BACKGROUND: The negative side effects of breast cancer treatments can include upper limb lymphoedema. The growing literature indicates that Nordic walking is an effective discipline against several disease symptoms. The aim of this study was to determine whether introduction to Nordic walking alone is effective against total body extracellular water and upper limb circumferences in breast cancer survivors compared to its combination with a series of specifically created exercises (i.e...
December 2016: Breast Care
https://www.readbyqxmd.com/read/28228711/cutaneous-metastasis-from-breast-tumour-seeding-in-percutaneous-needle-biopsy
#2
Imma Savarese, Federica Scarfì, Alessia Gori, Federica Papi, Antonietta D'Errico, Marta Grazzini, Piero Covarelli, Vincenzo De Giorgi
No abstract text is available yet for this article.
December 2016: Breast Care
https://www.readbyqxmd.com/read/28228710/her2-positive-neuroendocrine-breast-cancer-case-report-and-review-of-literature
#3
Arpine Gevorgyan, Giacomo Bregni, Giulia Galli, Elisa Zanardi, Filippo de Braud, Serena Di Cosimo
BACKGROUND: Neuroendocrine carcinoma is an uncommon histology for breast cancer. CASE REPORT: Our patient underwent right quadrantectomy for a neuroendocrine carcinoma in 1984 and had a bone relapse 30 years later. After thorough pathological and immunohistochemical analysis the diagnosis was confirmed and HER2 amplification was observed. Here we discuss the management, rationale and results of HER2-targeted therapy in advanced neuroendocrine breast carcinoma.
December 2016: Breast Care
https://www.readbyqxmd.com/read/28228709/targeted-therapies-in-her2-overexpressing-metastatic-breast-cancer
#4
REVIEW
Soumaya Labidi, Nesrine Mejri, Aymen Lagha, Nouha Daoud, Houda El Benna, Mehdi Afrit, Hamouda Boussen
Human epidermal growth factor receptor-2 (HER2) is amplified in 25-30% of breast cancers and is associated with aggressive disease and poorer survival. Multiple anti-HER2 targeted therapies have dramatically changed management and outcome of this subgroup, both in adjuvant and metastatic settings. Despite the improvement of survival thanks to trastuzumab, unclear mechanisms of resistance occur, which has led to the development of new anti-HER2 therapies such as lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1)...
December 2016: Breast Care
https://www.readbyqxmd.com/read/28228708/local-resection-of-primary-tumor-in-upfront-stage-iv-breast-cancer
#5
Thomas Kolben, Theresa M Kolben, Isabelle Himsl, Tom Degenhardt, Jutta Engel, Rachel Wuerstlein, Sven Mahner, Nadia Harbeck, Steffen Kahlert
BACKGROUND: This study aimed to identify the association of local surgery of the primary tumor in metastatic breast cancer (MBC) patients with overall survival (OS) and prognostic factors. PATIENTS AND METHODS: Patients with primary MBC (1990-2006) were included in our retrospective analysis (n = 236). 83.1% had surgery for the primary tumor. OS was evaluated using Kaplan-Meier estimates. Predictive factors for OS were determined. RESULTS: Median follow-up was 123 months for all patients still alive at the time of analysis...
December 2016: Breast Care
https://www.readbyqxmd.com/read/28228707/prognostic-role-of-her2-status-and-adjuvant-trastuzumab-treatment-in-lymph-node-negative-breast-cancer-patients-a-retrospective-single-center-analysis
#6
Nina Fokter Dovnik, Andraž Dovnik, Nina Čas Sikošek, Maja Ravnik, Darja Arko, Iztok Takač
BACKGROUND: The natural course of traditionally prognostically unfavorable human epidermal growth factor receptor 2 (HER2)-positive breast cancer has been changed by anti-HER2 therapy. It is not clear whether the prognosis for HER2-positive patients treated with adjuvant trastuzumab differs from that of HER2-negative patients. METHODS: We performed a retrospective study including patients with lymph node-negative invasive breast cancer treated at our institution in the period 2000-2009...
December 2016: Breast Care
https://www.readbyqxmd.com/read/28228706/the-pi3k-pathway-background-and-treatment-approaches
#7
REVIEW
Michael P Lux, Peter A Fasching, Michael G Schrauder, Alexander Hein, Sebastian M Jud, Claudia Rauh, Matthias W Beckmann
Two-thirds of all breast cancer patients with metastases have a hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative subtype. Endocrine therapy is the treatment of choice in these patients since in addition to its effectiveness it can also maintain the patients' quality of life over a longer term. However, 44-62% of postmenopausal patients with metastatic breast carcinoma have primary tamoxifen resistance. After 3-5 years, 30-40% of the patients receiving tamoxifen treatment develop secondary resistance...
December 2016: Breast Care
https://www.readbyqxmd.com/read/28228705/her2-orientated-therapy-in-early-and-metastatic-breast-cancer
#8
REVIEW
Severine Iborra, Elmar Stickeler
Due to the enhanced understanding of molecular oncology and signaling pathways in breast cancer (BC), therapy management has undergone a major transformation, especially with the emergence of treatment tailored to individual disease characteristics. In the case of HER2-positive early or metastatic BC, targeted therapies are well established and remain a major focus of ongoing research. The introduction of anti-HER2 biologicals such as trastuzumab, pertuzumab, and T-DM1 has made targeted and personalized treatment possible and has clearly improved disease-free and overall survival in patients with HER2-positive BC...
December 2016: Breast Care
https://www.readbyqxmd.com/read/28228704/pd-1-and-pd-l1-immune-checkpoint-blockade-to-treat-breast-cancer
#9
REVIEW
Andreas D Hartkopf, Florin-Andrei Taran, Markus Wallwiener, Christina B Walter, Bernhard Krämer, Eva-Maria Grischke, Sara Y Brucker
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer...
December 2016: Breast Care
https://www.readbyqxmd.com/read/28228703/pathway-oriented-therapy-in-breast-cancer-a-light-at-the-end-of-the-tunnel
#10
EDITORIAL
Eugen Ruckhäberle, Tanja Fehm
No abstract text is available yet for this article.
December 2016: Breast Care
https://www.readbyqxmd.com/read/27920631/invasive-lobular-carcinoma-of-the-breast-appearance-on-digital-breast-tomosynthesis
#11
Ahuva Grubstein, Yael Rapson, Sara Morgenstern, Itai Gadiel, Amit Haboosheh, Rinat Yerushalmi, Maya Cohen
BACKGROUND: The aim of this study was to characterize the signs of invasive lobular carcinoma of the breast on digital breast tomosynthesis (DBT) imaging. PATIENTS AND METHODS: The study group included 23 women with pathologically proven invasive lobular carcinoma of the breast for whom both digital mammography (DM) and DBT images were available. The images were read jointly by 2 experienced breast radiologists. Findings were recorded according to the descriptors in the Breast Imaging and Reporting Data System lexicon and correlated with the detailed pathology results...
October 2016: Breast Care
https://www.readbyqxmd.com/read/27920630/bilateral-diffuse-pseudoangiomatous-stromal-hyperplasia-pash-causing-gigantomastia-in-a-33-year-old-pregnant-woman-case-report
#12
Natalia Krawczyk, Tanja Fehm, Eugen Ruckhäberle, Svjetlana Mohrmann, Jasmin Riemer, Stefan Braunstein, Jürgen Hoffmann
Pseudoangiomatous stromal hyperplasia (PASH) is a benign proliferation of mammary stroma mostly described as an incidental microscopic finding. Clinically, it can manifest as a palpable, well-circumscribed breast mass or in rare cases as a diffuse bilateral process causing massive breast enlargement. The most postulated theory for aetiology of this condition is hormonal stimulation of mammary myofibroblasts, particularly by progesterone. A definite diagnosis of PASH is based on typical pathological findings like stromal hyperplasia and empty slit-like channels positive for myofibroblastic and negative for endothelial markers...
October 2016: Breast Care
https://www.readbyqxmd.com/read/27920629/electrochemotherapy-in-the-treatment-of-massive-multisite-breast-cancer-metastasis-to-the-skin-and-subcutaneous-tissue-a-case-report
#13
Mateusz Wichtowski, Paweł Potocki, Joanna Kufel-Grabowska, Joanna Streb, Dawid Murawa
BACKGROUND: Chest wall recurrence (CWR) from breast cancer after mastectomy is a difficult to treat disease. Electrochemotherapy (ECT) provides a safe, efficient, and non-invasive locoregional treatment approach in this setting. CASE REPORT: A 61-year-old woman presented with unresectable breast cancer recurrence to the skin and subcutaneous tissue for which numerous lines of treatment were unsuccessful. Between February 2015 and May 2015, the patient underwent 3 courses of ECT after which a spectacular regression of the cutaneous metastatic foci was observed...
October 2016: Breast Care
https://www.readbyqxmd.com/read/27920628/local-recurrence-after-breast-conserving-surgery-and-mastectomy-following-neoadjuvant-chemotherapy-for-locally-advanced-breast-cancer-a-meta-analysis
#14
REVIEW
Xiaodong Zhou, Yujie Li
BACKGROUND: Breast-conserving surgery (BCS) in patients with large tumors shrunk by neoadjuvant chemotherapy (NCT) remains controversial. We conducted a meta-analysis to evaluate the local recurrence rates in locally advanced breast cancer (LABC) patients receiving NCT comparing BCS with mastectomy. METHODS: Pubmed, Web of Knowledge, and Ovid's database were searched for studies concerning treatment for LABC from January 2000 to June 2015. A meta-analysis was performed to compare the recurrence rates of patients receiving BCS versus mastectomy following NCT...
October 2016: Breast Care
https://www.readbyqxmd.com/read/27920627/the-role-of-nsaids-in-breast-cancer-prevention-and-relapse-current-evidence-and-future-perspectives
#15
REVIEW
Demetrios Moris, Michalis Kontos, Eleftherios Spartalis, Ian S Fentiman
Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) have received considerable interest as potential chemopreventive agents. The aim of this review is to summarize the accumulated knowledge on the effect of NSAIDs on breast cancer incidence and natural history, and the underlying pathophysiology. NSAIDs mainly block inflammation by inhibiting cyclooxygenase enzymes, leading to lower prostaglandin synthesis. The latter has been reported to affect breast cancer risk through hormonal and inflammation-related pathways...
October 2016: Breast Care
https://www.readbyqxmd.com/read/27920626/evaluation-of-serum-vitamin-d-levels-in-adolescents-with-pubertal-gynecomastia
#16
Melis Pehlivantürk Kızılkan, Sinem Akgül, Filiz Akbıyık, Orhan Derman, Nuray Kanbur
BACKGROUND: Since vitamin D has an inhibitory function on ductal morphogenesis of the pubertal mammary gland, it may have a role in the development of gynecomastia. The aim of this study was to determine the effect of vitamin D deficiency on the development of pubertal gynecomastia. METHODS: Serum 25-hydroxyvitamin D (25D) levels in 50 adolescents with pubertal gynecomastia and 54 healthy controls between the ages of 11 and 17 years were compared. RESULTS: Mean 25D level was 14...
October 2016: Breast Care
https://www.readbyqxmd.com/read/27920625/a-retrospective-analysis-of-toxicity-and-efficacy-for-2-hypofractionated-irradiation-schedules-versus-a-conventional-one-for-post-mastectomy-adjuvant-radiotherapy-in-breast-cancer
#17
Vassilis Kouloulias, Eftychia Mosa, Anna Zygogianni, Efrosini Kypraiou, John Georgakopoulos, Kalliopi Platoni, Christos Antypas, George Kyrgias, Maria Tolia, Christos Papadimitriou, Amanda Psyrri, George Patatoukas, Maria Dilvoi, Christina Armpilia, Kyriaki Theodorou, Maria-Aggeliki Kalogeridi, Ivelina Beli, John Kouvaris, Nikolaos Kelekis
INTRODUCTION: The aim of this analysis was a retrospective evaluation of the efficacy and toxicity of 2 hypofractionated irradiation schedules compared to conventional therapy in post-mastectomy patients. METHODS: 3 irradiation schedules were analyzed: 48.30 Gy in 21 fractions (group A, n = 60), 42.56 Gy in 16 fractions (group B, n = 27) and 50 Gy in 25 fractions (group C, n = 30) of the front chest wall. All groups were also treated with a supraclavicular field, with 39...
October 2016: Breast Care
https://www.readbyqxmd.com/read/27920624/neoadjuvant-chemotherapy-with-docetaxel-carboplatin-and-weekly-trastuzumab-is-active-in-her2-positive-early-breast-cancer-results-after-a-median-follow-up-of-over-4-years
#18
Hans-Christian Kolberg, Leyla Akpolat-Basci, Miltiades Stephanou, Bahriye Aktas, Carla Verena Hannig, Cornelia Liedtke
INTRODUCTION: Most patients with HER2-positive breast cancer receive chemotherapy and trastuzumab. Data from adjuvant trials have shown that the combination of docetaxel, carboplatin and weekly trastuzumab (TCH) is well tolerated and as effective as anthracycline-containing regimes. Previous investigations on neoadjuvant treatment with taxanes, platinum salts and trastuzumab showed pathological complete remission (pCR) rates between 43.3 and 76%. To date, the longest published follow-up in this indication is 3 years...
October 2016: Breast Care
https://www.readbyqxmd.com/read/27920623/factors-influencing-decision-making-for-or-against-adjuvant-and-neoadjuvant-chemotherapy-in-postmenopausal-hormone-receptor-positive-breast-cancer-patients-in-the-evaluate-tm-study
#19
Paul Gaß, Peter A Fasching, Tanja Fehm, Johann de Waal, Mahdi Rezai, Bernd Baier, Gerold Baake, Hans-Christian Kolberg, Martin Guggenberger, Mathias Warm, Nadia Harbeck, Rachel Wuerstlein, Jörg-Uwe Deuker, Peter Dall, Barbara Richter, Grischa Wachsmann, Cosima Brucker, Jan W Siebers, Nikos Fersis, Thomas Kuhn, Christopher Wolf, Hans-Walter Vollert, Georg-Peter Breitbach, Wolfgang Janni, Robert Landthaler, Andreas Kohls, Daniela Rezek, Thomas Noesselt, Gunnar Fischer, Stephan Henschen, Thomas Praetz, Volker Heyl, Thorsten Kühn, Thomas Krauss, Christoph Thomssen, Andre Hohn, Hans Tesch, Christoph Mundhenke, Alexander Hein, Claudia Rauh, Christian M Bayer, Adib Jacob, Katja Schmidt, Erik Belleville, Peyman Hadji, Sara Y Brucker, Matthias W Beckmann, Diethelm Wallwiener, Sherko Kümmel, Christian R Löhberg
BACKGROUND: Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and be exposed to the associated toxicity. The aim of this study was to identify the patient population for whom this issue may bear relevance. METHODS: Patients being treated with letrozole in the prospective multicenter noninterventional EvAluate-TM study were recruited...
October 2016: Breast Care
https://www.readbyqxmd.com/read/27920622/neoadjuvant-treatment-of-breast-cancer-advances-and-limitations
#20
EDITORIAL
Peter A Fasching, Paul Gaß, Alexander Hein
No abstract text is available yet for this article.
October 2016: Breast Care
journal
journal
41130
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"